RxNews Recap for Wednesday 11-25-09 Print E-mail
By Mary Davila   
Wednesday, 25 November 2009 18:40

Below is a list of the companies that made news in the healthcare sector on Wednesday, November 25, 2009.


Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

Agilent Technologies Inc. (NYSE:A) today announced the following webcast for the investment community:  Credit Suisse Annual Technology Conference ThePhoenician, Scottsdale, Ariz.Tuesday, Dec. 1, at 9:30 a.m. MSTRon Nersesian, president, Electronic Measurement Group.

Ardea Biosciences, Inc. (Nasdaq:RDEA) announced today that Barry D. Quart, Pharm.D., president and chief executive officer, will present at the Piper Jaffray 21st Annual Health Care Conference.

AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced that the Company will present at the 21st Annual Piper Jaffray Health Care Conference on Wednesday, December 2nd at 2:30 p.m. Eastern time (11:30 a.m. Pacific time) at the New York Palace Hotel in New York.

Biomagnetics Diagnostics Corp., (OTC:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced the Company will hold an investor conference call to discuss upcoming business opportunities and its agreement with one of the world’s premiere research laboratories.

China Sky One Medical, Inc. (Nasdaq:CSKI), a leading fully integrated pharmaceutical company developing and producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the Company recently passed the Chinese National Institute for the Control of Pharmaceutical and Biological Products ("ICPBP") examination for two of its new products: its Diagnostic Kit for Human Prostate Specific Antigen (Colloidal Gold) and its Determination Kit for Luteinizing Hormone (Colloidal Gold).

Covidien (NYSE:COV) will present at the 21st Annual Piper Jaffray Health Care Conference in New York on Wednesday, December 2, 2009. Charles J. Dockendorff, Executive Vice President and Chief Financial Officer, will represent the Company in a session scheduled at 8:30 a.m. ET.

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the Piper Jaffray 21st Annual Healthcare Conference at 11:00 a.m. EST on December 2, 2009, in New York City.

Normal 0

Enzo Biochem, Inc. (NYSE:ENZ) announced today that its Board of Directors approved the termination of Shahram K. Rabbani’s services as the Company’s Secretary and Treasurer, respectively, effective immediately.

Exact Sciences Corp. (Nasdaq:EXAS) today announced that it will present at the Piper Jaffray Health Care Conference, which is being held Dec. 1-2, at the New York Palace Hotel.

GLG Life Tech Corporation (NASDAQ:GLGL), the vertically integrated leader in the agricultural and industrial development of high quality stevia extracts, announced today that it has completed its previously announced equity offering (the "Offering").

Human Genome Sciences, Inc. (Nasdaq:HGSI) today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.

Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), today announced that Novartis will terminate its research collaboration agreement with the Company, effective as of February 21, 2010.

Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Christy L. Shaffer, Ph.D., President and CEO, and Thomas R. Staab, II, CFO and Treasurer, will present at the 21st Annual Piper Jaffray Health Care Conference on Wednesday, December 2, 2009 at 10:00 am ET in New York City.

Illumina, Inc. (NASDAQ:ILMN) today announced that its Board of Directors has approved a new stock repurchase program, authorizing the company to repurchase in the aggregate up to $100 million of its outstanding common stock.

Incyte Corporation (NASDAQ:INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.

Medtronic, Inc. (NYSE:MDT), the world’s leading medical technology company, today announced it will participate in the 21st Annual Piper Jaffray Healthcare Conference on Tuesday, Dec. 1, 2009, in New York.

NuVasive, Inc. (Nasdaq:NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that it will host a conference call on Monday, November 30, 2009, at 5:30 p.m. ET / 2:30 p.m. PT.

Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell therapeutic company focused on developing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and Chief Executive Officer, is scheduled to present at the 21st Annual Piper Jaffray Healthcare Conference on Wednesday, December 2, 2009 at 9:30 a.m. EST.

Par Pharmaceutical Companies, Inc. (NYSE:PRX) today announced the results of its "Modified Dutch Auction" tender offer, in which Par offered no purchase, for cash, up to $65,000,000 aggregate principal amount, or up to approximately 82.7%, of its outstanding 2.875% Senior Subordinated Convertible Notes due 2010.

Unilife Medical Solutions Limited (ASX:UNI) (OTC:UNIFF) today announced the filing of patent applications in the United States ("US") for a new ready-to-fill syringe product to be marketed as the Unifill™ Select.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus